Lipid mRNA Bone Protein Synthesis Patent
Summary
USPTO granted Patent US12600990B2 to inventors Alexander Day and Bradford Mullin on April 14, 2026. The patent covers methods of using lipid-solubilized synthetic mRNA encoding bone morphogenic protein (BMP) and/or BMP receptor for intraoperative bone fusion applications. The patent contains 20 claims and was filed on October 3, 2022.
What changed
USPTO issued Patent US12600990B2 for methods of preparing and using synthetic mRNA encoding bone morphogenic protein and BMP receptor delivered via lipid carrier for bone fusion procedures. The patent describes intraoperative methods where a bone harvest sample is incubated with lipid-solubilized mRNA, allowing internalization and formation of activated BMP material for delivery to bone fusion beds.
For biotech and pharmaceutical companies developing mRNA-based bone regeneration therapies, this patent establishes intellectual property rights in the lipid-mRNA BMP synthesis space. Companies pursuing similar intraoperative bone fusion technologies should conduct freedom-to-operate analyses and consider licensing opportunities. The patent's broad claims covering both BMP and BMPR in lipid carriers may affect product development strategies in musculoskeletal therapeutics.
What to do next
- Monitor for updates
Archived snapshot
Apr 16, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
MRNA induced expression of bone morphogenic protein and receptor and methods related thereto
Grant US12600990B2 Kind: B2 Apr 14, 2026
Inventors
Alexander Day, Bradford Mullin
Abstract
Methods and treatments including preparing a synthetic messenger ribonucleic acid (mRNA) encoding at least for a bone morphogenic protein (BMP) and/or a BMP receptor. The synthetic mRNA is lipid-solubilized in a lipid or lipid derivative carrier. Intraoperatively, a bone harvest sample is obtained and incubated with the lipid-solubilized mRNA. The bone harvest sample internalizes at least a portion of the lipid-solubilized mRNA, thereby forming activated BMP and/or BMPR material. The activated BMP and/or BMPR material may be delivered intraoperatively to a bone fusion bed.
CPC Classifications
C12N 15/88 A61K 47/543 A61K 48/0041 C07K 14/51
Filing Date
2022-10-03
Application No.
18246062
Claims
20
Related changes
Get daily alerts for USPTO Patent Grants - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.